Lin-Hung Wei

Title: Lin-Hung Wei: Innovator in Interleukin-6 Research

Introduction

Lin-Hung Wei is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic peptides. His innovative work focuses on targeting interleukin-6, a cytokine involved in various inflammatory processes and diseases.

Latest Patents

Lin-Hung Wei holds a patent for an "Oligopeptide antagonist of interleukin-6." This invention provides an antagonist peptide of interleukin-6 (IL-6), which comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7. The peptide is designed to specifically bind to IL-6R, competing for the binding of IL-6 to IL-6R. This mechanism effectively blocks IL-6-induced signal transduction, inhibiting IL-6-mediated anti-apoptosis, angiogenesis, and tumor growth. Lin-Hung Wei has 1 patent to his name.

Career Highlights

Lin-Hung Wei is affiliated with National Taiwan University, where he conducts his research and development activities. His work has garnered attention for its potential applications in treating diseases associated with IL-6, including certain cancers and inflammatory conditions.

Collaborations

Lin-Hung Wei collaborates with notable colleagues such as Jen-Liang Su and Min-Liang Kuo. Their combined expertise enhances the research efforts and innovation in the field of peptide therapeutics.

Conclusion

Lin-Hung Wei's contributions to the understanding and treatment of interleukin-6 related conditions highlight his role as an influential inventor in biomedical research. His innovative patent demonstrates the potential for new therapeutic approaches in managing diseases linked to this critical cytokine.